Incyte (INCY) Restructuring Costs (2010 - 2016)

Incyte (INCY) posted Restructuring Costs of $1.6 million for Q4 2016, up 6.67% on a QoQ basis from $1.5 million in Q3 2016.

Incyte (INCY) Restructuring Costs (2010 - 2016) Analysis & Trends

Incyte's Restructuring Costs history runs 3 years deep, the most recent figure standing at $1.6 million for Q4 2016.

Quarterly Restructuring Costs changed N/A year-over-year to $1.6 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $4.4 million (changed N/A YoY) and the FY2016 annual result came in at $1.6 million, changed N/A from the prior year.
Restructuring Costs was $1.6 million for Q4 2016 at Incyte, up from $1.5 million in the prior quarter.
Across five years, Restructuring Costs topped out at $1.6 million in Q4 2016 and bottomed at $1.3 million in Q2 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Incyte	23.47 Bn	19.46 Bn	1.17 Bn

Download Data